Europe Gene Synthesis Market

Europe Gene Synthesis Market Size (2023 to 2028)

The gene synthesis market size in Europe is estimated to grow from USD 1.32 billion by 2028 from USD 0.66 billion in 2023, growing at a CAGR of 14.99% from 2023 to 2028.

The growing prevalence of genetic disorders and increasing need for effective solutions drive the growth of the Europe gene synthesis market during the forecast period. Gene synthesis is a key aspect of synthetic biology that enables the creation of artificial genes in laboratory settings without the need for a template. Genetic disorders arise from harmful gene alterations and can have significant impacts on individuals' health. Factors such as radiation exposure, chemical exposure, smoking and UV exposure contribute to the occurrence of these disorders. Researchers and healthcare providers are actively engaged in developing drugs and vaccines to address these conditions due to the growing patient population suffering from genetic disorders. Drug development is a complex and costly process. However, the utilization of gene synthesis in drug development enables a more efficient and cost-effective approach. This technology plays a crucial role in the development of drugs and vaccines, facilitating the treatment and prevention of diseases, especially in children. With a focus on rare diseases and the increasing number of cases, the demand for gene synthesis in drug development is expected to drive the growth of the European gene synthesis market.

The growing geriatric population contributes to the advancement of the gene synthesis market in Europe. Gene therapy holds significant potential in addressing health issues associated with aging and reducing mortality rates. Older individuals often experience significant muscle mass loss due to factors such as reduced food intake, limited physical activity, and the use of medications for various conditions. To combat this muscle loss and improve the well-being of the elderly population, healthcare providers are utilizing gene therapies. These innovative therapies play a vital role in the market's development, offering promising solutions for age-related health challenges.

The advancements in gene synthesis technology further support the growth of the European market. The continuous progress in advanced technologies and equipment facilitates the production of more effective solutions. The growing demand for personalized medicine and targeted therapies, rising investments in research and development activities related to gene synthesis and supportive government initiatives and funding for genetic research and healthcare propel the growth of the European market. The growing applications of gene synthesis in fields such as agriculture, biotechnology, and pharmaceuticals, rapid adoption of gene editing tools like CRISPR-Cas9 for precise genetic modifications and growing awareness and acceptance of gene therapy as a potential treatment option further boost the growth rate of the European gene synthesis market.

Ethical and regulatory concerns surrounding gene synthesis and genetic manipulation is one of the key factors hampering the market growth. Limited availability of skilled professionals and researchers in the field of gene synthesis and high cost associated with gene synthesis technologies, equipment, and services further hinder the regional market growth. Concerns regarding intellectual property rights and patent issues related to gene synthesis and challenges in scaling up gene synthesis processes to meet the demand for large-scale production are potential roadblocks to the growth rate of the European market. Stringent regulatory requirements and approval processes for gene therapy products, potential safety and efficacy concerns associated with gene therapies and genetically modified organisms, limited reimbursement policies for gene therapy treatments and services and lack of public awareness and understanding of the benefits and risks of gene synthesis and gene therapy inhibits the growth rate of the European market.

This research report on the Europe gene synthesis market has been segmented and sub-segmented into the following categories.

By Method:

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

By Services:

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

By Application:

• Gene & Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

By End-use:

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Contract Research Organizations

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Europe occupied a considerable share of the global market in 2022 and is estimated to showcase a promising occupancy in the worldwide market during the forecast period. Germany is anticipated to account for the major share of the European market during the forecast period owing to the widespread adoption of gene therapies for various diseases and the establishment of specialized hospitals dedicated to gene therapies. Personalized medicine, achieved through gene synthesis, has become a significant factor in disease prevention and treatment. Germany, with its abundance of laboratories and key industry players and bolstered by a robust pipeline of product launches and an increasing incidence of infectious diseases. Similarly, the United Kingdom has a notable presence, benefiting from its thriving biotechnology and pharmaceutical sectors, as well as the proliferation of research centers focused on cell and gene development.

KEY MARKET PLAYERS:

Eurofins Genomics, Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation and Eurogentec are some of the notable companies in the Europe gene synthesis market.